
Controlled Clinical Trials

DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 14, Number 1, 1993

Contents

STEPHEN SENN

- Suspended Judgment* *n*-of-1 Trials 1

MICHAEL S. SIMBERKOFF, PAMELA M. HARTIGAN, JOHN D. HAMILTON,
DANIEL DEYKIN, MITCHELL GAIL, JOHN G. BARTLETT, PAUL FEORINO,
ROBERT REDFIELD, RICHARD ROBERTS, DOROTHEA COLLINS, DAVID DEMETS,
WILLIS PRITCHETT, NORTON SPRITZ, RICHARD P. WENZEL, AND THE VA
COOPERATIVE STUDY GROUP ON AIDS TREATMENT, VA MEDICAL CENTER,
NEW YORK, NEW YORK

- Ethical Dilemmas in Continuing a Zidovudine Trial After
Early Termination of Similar Trials 6

PAUL R. COE AND AJIT C. TAMHANE

- Exact Repeated Confidence Intervals for Bernoulli Parameters in a Group
Sequential Clinical Trial 19

CAROLYN SIEBERT

- Operational and Policy Considerations of Data Monitoring in Clinical Trials:
The Diabetes Control and Complications Trial Experience 30

DAVID WATERS, LYALL HIGGINSON, PETER GLADSTONE, BRIAN KIMBALL,
MICHEL LEMAY, AND JACQUES LESPÉRANCE

- Design Features of a Controlled Clinical Trial to Assess the Effect
of an HMG CoA Reductase Inhibitor on the Progression of
Coronary Artery Disease 45

Volume 14, Number 2, 1993

ALAN H. JOBE

- Suspended Judgment* Simple Explanations for Complex Systems:
Surprising and Unexpected Outcomes 75

STEVEN D. MARK AND JAMES M. ROBINS

- A Method for the Analysis of Randomized Trials with Compliance
Information: An Application to the Multiple Risk Factor Intervention Trial 79

TERRY M. THERNEAU

- How Many Stratification Factors Are "Too Many" to Use in a
Randomization Plan? 98

JERRY HALPERN AND BYRON WM. BROWN JR. A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing	109
PATRICIA A. CLEARY, ROY W. BECK, MAI COLM M. ANDERSON, DAVID J. KENNY, JYE-YU BACKLUND, PETER R. GILBERT, AND THE OPTIC NEURITIS STUDY GROUP Design, Methods, and Conduct of the Optic Neuritis Treatment Trial	123
JOHN L. KELTNER, CHRIS A. JOHNSON, ROY W. BECK, PATRICIA A. CLEARY, JOHN O. SPURR, AND THE OPTIC NEURITIS STUDY GROUP Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT)	143
PMA BIOSTATISTICS AND MEDICAL AD HOC COMMITTEE ON INTERIM ANALYSIS Interim Analysis in the Pharmaceutical Industry: The PMA Position	160
GEORGE L. SPAETH <i>Letter to the Editor</i> Concerning Silverman's Suspended Judgment Article "The Most Noble Goal of Medicine" Published December 1991	174
JOHN R. HUGHES <i>Letter to the Editor</i> Exclusion of "Noncompliant" Individuals from Clinical Trials	176

Volume 14, Number 2, 1993

Supplement

The Lung Health Study: Design of the Trial and Recruitment of Participants

THE LUNG HEALTH STUDY RESEARCH GROUP The Lung Health Study: Introduction	1S
JOHN E. CONNETT, JOHN W. KUSEK, WILLIAM C. BAILEY, PEGGY O'HARA, AND MARGARET WU FOR THE LUNG HEALTH STUDY RESEARCH GROUP Design of the Lung Health Study: A Randomized Clinical Trial of Early Intervention for Chronic Obstructive Pulmonary Disease	3S
DEBORAH A. DURKIN, MARCUS O. KJELSBERG, A. SONIA BUIST, JOHN E. CONNETT, GREGORY R. OWENS, AND RECRUITMENT DIRECTORS OF THE LUNG HEALTH STUDY FOR THE LUNG HEALTH STUDY RESEARCH GROUP Recruitment of Participants in the Lung Health Study, I: Description of Methods	20S
JOHN E. CONNETT, WENDY M. BJORNSEN-BENSON, AND KATHLEEN DANIELS, FOR THE LUNG HEALTH STUDY RESEARCH GROUP Recruitment of Participants in the Lung Health Study, II: Assessment of Recruiting Strategies	38S
WENDY M. BJORNSEN-BENSON, THOMAS B. STIBOLT, KENNETH A. MANSKE, KATHLEEN J. ZAVELA, DIANA J. YOUTSEY, AND A. SONIA BUIST Monitoring Recruitment Effectiveness and Cost in a Clinical Trial	52S
CATHY RUDICK, NICHOLAS R. ANTHONISEN, AND JURE MANFREDI Recruiting Healthy Participants for a Large Clinical Trial	68S
Appendix: Lung Health Study Participants	80S

Volume 14, Number 3, 1993

HEINZ W. BERENDES AND YOUNG J. LEE <i>Suspended Judgment</i> The 1953 Clinical Trial of Diethylstilbestrol During Pregnancy: Could It Have Stopped DES Use?	179
THOMAS R. FLEMING AND DAVID L. DEMETS Monitoring of Clinical Trials: Issues and Recommendations	183
JONATHAN J. SHUSTER Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach	198
JEAN-MAURICE DUMONT Effect of Cholesterol Reduction by Simvastatin on Progression of Coronary Atherosclerosis: Design, Baseline Characteristics, and Progress of the Multicenter Anti-Atheroma Study (MAAS)	209
THE ODES INVESTIGATORS The Oslo Diet and Exercise Study (ODES): Design and Objectives	229
ROBERT P. MCMAHON <i>Letter to the Editor</i> In Response to an Article by Lemuel Moye (CCT 12(6)) Entitled 'Central Laboratory Sampling Plans and Quality Control in Clinical Trials'	244
NICHOLAS LANGE <i>Letter to the Editor</i> In Response to an Article by Lemuel Moye (CCT (12(6)) Entitled 'Central Laboratory Sampling Plans and Quality Control in Clinical Trials'	247
LEMUEL A. MOYE <i>Letter to the Editor</i> Response to McMahon and Lange	249
THOMAS A. LOUIS <i>Book Review</i> Medical Statistics: A Commonsense Approach by Michael J. Campbell and David Machin	251
MITCHELL H. GAIL AND DONALD K. CORLE Erratum	253

Volume 14, Number 4, 1993

CURTIS L. MEINERT <i>Editorial</i> In Defense of the Corporate Author for Multicenter Trials	255
PHILIP PETTIT <i>Suspended Judgment</i> Instituting a Research Ethic	261
JOHN W. TUKEY Tightening the Clinical Trial	266
EDWARD L. KORN, KAI F. YU, AND LANGDON L. MILLER Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence	286

ETTORE MARUBINI, MARIO BRAGA, MARIA LEA CORREA LEITE, ANNA PETROCCIONE, NICOLETTA PIROTTA, ON BEHALF OF SINBA GROUP "Within Patient"—Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass	296
MARK D. THORNQUIST, GILBERT S. OMENN, GARY E. GOODMAN, JAMES E. GRIZZLE, LINDA ROSENSTOCK, SCOTT BARNHART, GARNET L. ANDERSON, SAMUEL HAMMAR, JOHN BALMES, MARTIN CHERNIACK, JAMES CONE, MARK R. CULLEN, ANDREW GLASS, JAMES P. KEOGH, FRANK MEYSKENS, JR., BARBARA VALANIS, AND JAMES H. WILLIAMS, JR. Statistical Design and Monitoring of the Carotene and Retinol Efficacy Trial (CARET)	308
MARK D. THORNQUIST, NICOLE URBAN, ADELINA TSENG, CIM EDELSTEIN, BERNEDINE LUND, AND GILBERT S. OMENN Research Cost Analyses to Aid in Decision Making in the Conduct of a Large Prevention Trial, CARET	325
GEORGE L. SPAETH <i>Letter to the Editor</i>	340
JEAN-PIERRE BOISSEL <i>Response to Letter to the Editor</i>	344

Volume 14, Number 5, 1993

WILLIAM A. SILVERMAN <i>Suspended Judgment</i> From "Tame" to "Forbidden" Death	347
BARRY R. DAVIS, JANET WITTES, SARA PRESSEL, KENNETH G. BERGE, C. MORTON HAWKINS, EDWARD LAKATOS, LEMUEL A. MOYÉ, AND JEFFREY L. PROBSTFIELD Statistical Considerations in Monitoring the Systolic Hypertension in the Elderly Program (SHEP)	350
THE COLLABORATIVE OCULAR MELANOMA STUDY GROUP Design and Methods of Clinical Trial for a Rare Condition: The Collaborative Ocular Melanoma Study: Report No. 3	362
Announcement	392
Final Program: Fourteenth Annual Meeting of the Society for Clinical Trials	393
Abstracts: Fourteenth Annual Meeting of the Society for Clinical Trials	399

Volume 14, Number 6, 1993

TONSE N.K. RAJU, PATRICIA LANGENBERG, AND ASHISH SEN <i>Suspended Judgment</i> Treatment Effect Size in Clinical Trials: An Example from Surfactant Trials	467
--	-----

WILLIAM F. ROSENBERGER AND JOHN M. LACHIN	
The Use of Response-Adaptive Designs in Clinical Trials	471
RICHARD D. GELBER, ARON GOLDBIRSCH, AND BERNARD F. COLE	
FOR THE INTERNATIONAL BREAST CANCER STUDY GROUP	
Parametric Extrapolation of Survival Estimates with Applications to	
Quality of Life Evaluation of Treatments	485
HENRY BUCHWALD, LAURIE L. FITCH, JOHN P. MATTS, JAMES W. JOHNSON,	
BETTY J. HANSEN, MERIDITH R. STUENKEL, AND HELENE B. BROOKS FOR	
THE POSCH GROUP	
Perception of Quality of Life Before and After Disclosure of Trial Results: A	
Report from the Program on the Surgical Control of the Hyperlipidemias	
(POSCH)	500
BERCEDIS PETERSON AND STEPHEN L. GEORGE	
Sample Size Requirements and Length of Study for Testing Interaction	
in a $2 \times k$ Factorial Design When Time-to-Failure Is the Outcome	511
LINDA L. ROSENDORF, URANIA DAFNI, DAVID A. AMATO, BARBARA	
LUNGHOFFER, JOHN G. BASRTLETT, JOHN M. LEEDOM, DIANE W. WARA,	
JOHN A. ARMSTRONG, ELLEN GODFREY, EVIND SUKKESTAD, AND	
GEORGE W. COUNTS	
Performance Evaluation in Multicenter Clinical Trials: Development of a	
Model by the AIDS Clinical Trial Group	523
JOHN W. KUSEK, TERRY COYNE, ANN DE VELASCO, MARTIN J. DRABIK,	
R. ALLAN FINLAY, JENNIFER J. GASSMAN, SALLY KIEFER,	
SANDRA N. POWERS, AND THEODORE I. STEINMAN	
Recruitment Experience in the Full-Scale Phase of the Modification	
of Diet in Renal Disease Study	538
Petition Regarding the 103rd Congressional Mandate	558
Directive to the Director of the NIH	559
ARGYE HILLIS	
<i>Letter to the Editor</i> The Role of Clinical Research in Containing Health Care	
Costs	560
STEVEN PIANTADOSI AND JANET WITTES	
<i>Letter to the Editor</i> Politically Correct Clinical Trials	562
JOHN McKELLAR	
<i>Letter to the Editor</i> Note on the Value of 24-Hour Ambulatory Blood	
Pressure Devices	568
LAWRENCE J. APPEL	
<i>Letter to the Editor</i> In Response to Letter "Note on the Value of 24-Hour	
Ambulatory Blood Pressure Devices"	569
Reviewers of Controlled Clinical Trials	570
Volume 14 Author Index	572
Volume 14 Subject Index	574
Volume Contents	